Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment

Summary

Vaderis Therapeutics, a 13-person Swiss startup, raised $152 million in Series B funding to advance a Phase 3 trial for a cancer-derived treatment approach in a rare bleeding disorder.